Skip to main content

Table 1 Study of the various known pathological factors in AD

From: Impact of the biological definition of Alzheimer’s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?

Factor Imaging CSF Blood Potential RX
Amyloid-β load [11C]PIB
Amyloid-β(1–42) APP669–711;
BACE inhibitors
Amyloid-β immunotherapy
Neurofibrillary tangles load [18F]MK6240
Phosphorylated tau The association of serum phosphorylated tau with tangles is unclear Anti-aggregation
Tau immunotherapy
Neurodegeneration MRI
Neurofilament light chain (NFL); d neurogranin (Ng);
Visinin-like protein-1 (VILIP-1); Synaptosomal-associated protein 25 (SNAP-25);
Neuron-specific enolase (NSE); Heart fatty acid binding protein (HFABP)
Neurofilament light chain (NFL) Neurotrophic factors
Vascular load MRI CSF albumin /plasma albumin ratio Control of risk factors
Lewy Body load NA α-synuclein α-synuclein α-synuclein immunotherapy
Neuroinflammation activity Microglial Activation:
[18F] DPA714
[11C] DPA713
Reactive astrocytes:
Microglial Activation:
Chitinase-3-like protein 1 (YKL-40), soluble TREM2 (sTREM2)
TNF-α, IL-6, IL-1β
Chemokines: monocyte chemotactic protein 1 [MCP-1]
Microglial Activation:
Chitinase-3-like protein 1 (YKL-40)
TNF-α, IL-6, IL-1β,
Chemokines: monocyte chemotactic protein 1 [MCP-1]
Peroxisome proliferator-activated receptor-γ
(PPAR-γ) activators
TNF-α inhibitor